BTCY

Biotricity Inc

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Biotricity Inc (BTCY) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 18.0
Rev Growth YoY 14.8%
Gross Margin 80.9%
Price Return 3M -53.6%
Price Return 12M -78.2%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.1
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) C+ (2.5) C- (2.1) C (2.4) C- (1.9) C (2.3)
2026-08-04 C+ (2.7) C+ (2.5) C- (2.1) C (2.4) C- (1.9) C (2.3)
2026-08-03 C+ (2.7) C (2.5) C (2.4) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C (2.4) C (2.3) C (2.4) C- (1.9) C (2.4)